Please login to the form below

Not currently logged in
Email:
Password:
I have forgotten my password

gout

This page shows the latest gout news and features for those working in and with pharma, biotech and healthcare.

Ironwood claims FDA OK for former AZ gout drug

Ironwood claims FDA OK for former AZ gout drug

Ironwood claims FDA OK for former AZ gout drug. Duzallo will be launched in the US before the end of this year. ... The US FDA has approved Ironwood Pharma's combination gout therapy Duzallo, but with a warning that it can cause serious kidney failure.

Latest news

More from news
Approximately 9 fully matching, plus 42 partially matching documents found.

Latest Intelligence

  • Grünenthal's relentless pursuit of relief Grünenthal's relentless pursuit of relief

    We are involved in projects that go beyond pain - backed by our licence agreement with AstraZeneca for Zurampic in gout, a condition that causes joint pain flares and is diagnosed both

  • Deal Watch January 2017 Deal Watch January 2017

    230. Cymabay. Kowa. Exclusive licence in the US. Arhalofenate for gout p3 ready.

  • Deal Watch October 2016 Deal Watch October 2016

    Gout 2016. Ironwood. Lesinurad US. $265m royalties. Rhinitis 2016. Janssen. Rhinocort outside US.

  • Deal Watch June 2016 Deal Watch June 2016

    Zurampic, a Selective Uric Acid Reabsorption Inhibitor (SURI), works selectively to complement xanthine oxidase inhibitors (XOIs) in the treatment of hyperuricaemia associated with uncontrolled gout, and was approved by the EMA ... licence. 270.

  • Deal Watch April 2016 Deal Watch April 2016

    Another deal worth pondering about is the $265m exclusive license by AstraZeneca (AZ) of the approved Zurampic (lesuranid) plus a fixed dose combination with allopurinol for treatment of gout. ... 450. AstraZeneca (UK). Ironwood (US). US license and

More from intelligence
Approximately 0 fully matching, plus 6 partially matching documents found.

Latest from PMHub

  • THE OTHER SIDE OF … GOUT

    THE OTHER SIDE OF … GOUT. “ I thought that prolonged treatment would control the symptoms and enable me to live a near to normal life”. ... She also has gout, an inflammatory condition that affects one in 40 adults in the UK and is on the rise.

  • Patient Perspective: Gout

    Patient Perspective: Gout. What is it like to live with gout? ... Listen to a first-hand account of the symptoms of gout, and how Graham manages his condition.

  • THE OTHER SIDE OF … GOUT

    THE OTHER SIDE OF … GOUT. “ I thought that prolonged treatment would control the symptoms and enable me to live a near to normal life”. ... She also has gout, an inflammatory condition that affects one in 40 adults in the UK and is on the rise.

  • Redline Strategic

    THE OTHER SIDE OF … GOUT. “

  • Redline Strategic

    THE OTHER SIDE OF … GOUT. “

More from PMHub
Approximately 3 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Cello Health Insight

Cello Health Insight is the global market research arm of Cello Health. With 35 years’ sector experience, we specialise in...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Quick links

Infographics

Multimedia